Funding for Faculty

Additional Details

RFP Snapshot: The Siteman Cancer Center (SCC) Biostatistics and Qualitative Research Shared Resource (BQSR) fulfills a critical function by providing methodologic and analytic support for the development and conduct of scientifically sound, innovative cancer research at SCC. Advances in biotechnologies and computing systems/software increasingly require specialized expertise and tools for sophisticated statistical methodologies. Qualitative research requires sound methods and approaches that support rigor and best practice. The overarching goal of the BQSR is to provide a comprehensive, centralized, and accessible biostatistics and qualitative support infrastructure for all phases of cancer research; from study development and design to data collection, ongoing monitoring, and final analysis.

Max Amount and Period: N/A

Eligibility: Must be a Siteman Cancer Center member.

Due Date: Rolling

Additional Details

RFP Snapshot: The WUSTL Center for Drug Discovery offer the CDD Match Grant15 and Grant25 programs.

Match Grant15 is to advance translational small-molecule drug discovery research at Washington University. CDD offers a full suite of preclinical drug discovery services and know-how. Capabilities range from drug lead finding utilizing the High Throughput Screening Core to Medicinal Chemistry-driven drug lead optimization, ADME profiling, and in vivopharmacokinetics for proof-of-concept in vivo pharmacology studies, intellectual property (patent) filing, and drug development.

Match Grant25 is a follow-on award program meant only for those investigators who have successfully completed and met the objectives of a Match Grant15 (or the original CDD MicroGrant) award and request additional match funds to further advance the discovery research project. CDD offers a full suite of preclinical drug discovery services and know-how. Capabilities range from drug lead finding utilizing the High Throughput Screening Core to Medicinal Chemistry-driven drug lead optimization, ADME profiling, and in vivo pharmacokinetics for proof-of-concept in vivo pharmacology studies, intellectual property (patent) filing, and drug development.

Max Amount and Period:

Match Grant15 – $7,500 from CDD

Match Grant25 – $12,000 from CDD

Eligibility:

Match Grant15 – open to investigators with a faculty appointment at Washington University

Match Grant25 – open only to WashU faculty who have successfully completed a Match Grant15 (or CDD MicroGrant) and submitted a final research report.

Due Date: Rolling

Additional Details

RFP Snapshot: The purpose of the awards is to advance initial discovery pilots for Precision Health ICTS investigators. Proposals are not for developed projects but are to fund developmental or early stage work, including pilot data collection and analysis, in preparation for submission of future external funding.

Max Amount and Period: $25,000 for 1 year

Eligibility: Applicants must be full time faculty (instructor level or above) at Washington University in St. Louis or an ICTS partner institution. Applicant must be a member of the ICTS.

Due Date: Rolling

Additional Details

RFP Snapshot: The Just-In-Time (JIT) Core Usage Funding Program is designed to provide quick access to funding to use any of the JIT Cores (pdf) for research advancing medical knowledge that can improve human health. Siteman Cancer Center will co-sponsor cancer-focused proposals.

Max Amount and Period: Varies

Eligibility: Applicant must be a registered member of the ICTS and hold a faculty level appointment at WUSTL or an ICTS partner institution.

Due Date: Rolling

Additional Details

RFP Snapshot: There is a special emphasis on projects that accelerate existing preclinical and clinical research that increases therapeutic options, improves adjuvant therapies, delivers novel therapies focused on driver mutations (BRAF, TP53, KRAS, BRCA1, as examples) and investigate strategies to influence the tumor microenvironment (TME) to expand the use of immunotherapy. See RFA for other eligible research objective priorities.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applications will be accepted from non-profit, for-profit, and academic organizations, and from investigators who hold MD, PhD, or other professional degrees.

Due Date: Rolling

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: Pioneering Ideas: Exploring the Future to Build a Culture of Health welcomes proposals that are primed to influence health equity in the future. We seek ideas that address any of RWJF’s Pioneering Ideas for an Equitable Future team’s four current areas of focus described below: 1) Future of Evidence; 2) Future of Social Interaction; 3) Future of Food; and 4) Future of Work. Additionally, under Open Exploration, also described below, this call for proposals seeks ideas that might fall outside of these four focus areas but which offer unique approaches to advancing health equity and our progress toward a Culture of Health.

Max Amount and Period: No limit for 3 years, but budget must be reasonably supported by scope of project.

Eligibility: Applicant organizations must be based in the US or its territories. Preference will be given to applicant organizations that are either institutes of higher education, public entities, or nonprofits that are tax exempt under Section 501(c)(3) of the Internal Revenue Code.

Due Date: Rolling

Additional Details

RFP Snapshot: The key objective of this funding opportunity is to promote the establishment of a new generation of basic and translational scientists interested in tackling inherited hematologic malignancy predisposition disorders with a focus on RUNX1-familial platelet disorder. We believe that providing capital to early career investigators not only injects funding to where it is needed most, but also cultivates a new cohort of investigators who will be invested in an area of research that historically has had limited attention.

Max Amount and Period: $180,000 over 3 years

Eligibility: Applicants must have a doctoral degree and be within five years of their first faculty appointment as an Assistant Professor or equivalent tenure-track position. Associate and Full Professors are ineligible. If at the Instructor level, the applicant must submit a letter of support from their mentor at the sponsoring institution. A minimum of 75% of the applicant’s time during the award period must be allocated as protected time for all research activities. This percentage of time includes both activities on this grant and the applicant’s other research responsibilities. Applicants may have research grants from other funding sources during the award period, but there must be clear documentation of mechanisms to avoid scientific and budgetary overlap. Applicants must have research experience working in, and a deep understanding of, normal or malignant hematopoiesis and/or immunology

Due Date: December 19, 2024 at 7pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The intent of this program is to provide seed funding for highly innovative pancreatic cancer research with significant potential to accelerate the mission of the Lustgarten
Foundation. Proposals should address key outstanding questions and have the potential to lead to a change in the current paradigm or conventional wisdom. Proposals that involve collaborations across groups or that bring new expertise and/or technology into the field will be preferred. Preference will also be given to proposals addressing understudied and/or poorly understood aspects of pancreatic cancer biology.

Max Amount and Period: $100,000 for 1 year

Eligibility: See RFA.

Due Date: January 6, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: To foster and develop talented early-career breast radiation oncology researchers who are members of the populations that are currently underrepresented in biomedical research

Max Amount and Period: $100,000 for 1 year

Eligibility: Applicant must self-identify as a member of any of the “Underrepresented Populations in the U.S. Biomedical, Clinical, Behavioral and Social Sciences Research Enterprise” as listed in the Notice of NIH’s Interest in Diversity (NOT-OD-20-031). At the time of application, an eligible individual must hold at least one terminal degree such as PhD, MD, MD/PhD, or other equivalent degrees in medicine or the sciences, and be an early stage investigator (ESI) as defined as NIH’s ESI Policy. Generally, residents, postdoctoral fellows, or other trainees are not eligible to apply.

Due Date: January 10, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: PCORI aims to fund studies that address high-priority gaps in the science of engagement in research focused on development and/or assessment of validity of measures and the evaluation of engagement methods. For measurement proposals, PCORI will give preference to projects that rapidly develop and/or assess the validity of measures of engagement.

Max Amount and Period:

• $1M over 2 years – Category 1 – Development and/or assessment of validity of measures to capture structure/context, process, and outcomes of engagement in research.
• $1.5M over 3 years – Category 2 – Development and/or testing of engagement methods to generate evidence on the most effective approaches for engagement in research, particularly for underrepresented populations, and how effectiveness varies by context.

Eligibility: Applications for the conduct of research and management of funding may be submitted by appropriate academic research, private sector research, or study-conducting entities.

Due Date: Letter of Intent Due: January 14, 2025 at 4pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: PCORI aims to fund studies that address high-priority methodological gaps in comparative clinical effectiveness research (CER). Priority areas include 1) methods related to ethical and human subjects protections (HSP) issues in patient-centered CER, 2) methods to improve study design, 3) methods to support data research networks, and 4) methods to improve use of artificial intelligence and machine learning in clinical research.

Max Amount and Period: $750,000 over 3 years

Eligibility: Applications for the conduct of research and management of funding may be submitted by appropriate academic research, private sector research, or study-conducting entities.

Due Date: Letter of Intent Due: January 14, 2025 at 4pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: Candidates selected for this award are expected to be the future leaders in the field of cancer immunotherapy, and this sustained funding will enable them to carry out transformational research. Because the funds are not restricted to a particular project, the award allows the recipients to follow new and promising lines of investigation, which often lead to unanticipated scientific breakthroughs. This long-term funding provides a degree of flexibility and freedom to explore outside-the-box and disruptive avenues of research.

Max Amount and Period: $1.25M over 5 years

Eligibility: The applicant must have a MD, PhD, or MD/PhD and must either be a tenure-track Assistant Professor with a minimum of 3 years in this position (by the deadline) or be a tenure-track Associate Professor with a maximum of 3 years in this position (by the deadline). Applicants are expected to commit a minimum of 80% of their time to research. CRI has no citizenship restrictions, and research supported by the award may be conducted at medical schools and research centers in the United States or abroad.

Due Date: January 15, 2025 at 4pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The BTFC is prepared to sponsor research on liquid biopsy with the hope of advancing the technology to make liquid biopsy a viable option for brain tumor patient care. This Request for Letters of Intent focuses on supporting studies on liquid biopsy in primary brain tumors in pediatric, adolescent and young adult (AYA) and/or adult patients.

Max Amount and Period: $500,000 over 2 years

Eligibility: The applicant team should represent the requisite skills to carry out the proposed research including close collaboration between clinical oncology, radiology, tumor biology, computational modelling, and data science.

Due Date: Letter of Intent Due: January 16, 2025 at 5pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This grant opportunity is intended to fund innovative research projects in breast and gynecologic cancers and to invest in the next generation of female early-stage scientists domestically and globally. The aim of this award is to foster innovation in the understanding, prevention, interception, early detection, diagnosis, and treatment of breast and gynecologic cancers with the goal of eliminating cancer health disparities and improving patient outcomes. The research proposed for funding may be in basic, translational, clinical, or population sciences.

Max Amount and Period: $206,000 over 2 years

Eligibility: Applicants must be female investigators at the Assistant Professor level with a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Applicants belonging to racial or ethnic groups shown to be underrepresented in the cancer-related sciences workforce* are especially encouraged to apply. These groups include Blacks or African Americans, Hispanics or Latinos, American Indians or Alaska Natives, Native Hawaiians and other Pacific Islanders. Applicants must have started their first independent faculty position within the past 6 years and be able to devote at least 75% of their total effort to research in breast or gynecologic cancer. There are no citizenship requirements.

Due Date: Letter of Intent Due: January 23, 2025 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This grant opportunity is intended to fund innovative research projects in breast and gynecologic cancers and to invest in the next generation of female scientists at the Associate Professor level domestically and globally to foster innovation in the understanding, prevention, interception, early detection, diagnosis, and treatment of these cancers with the goal of eliminating cancer health disparities and improving patient outcomes. The research proposed for funding may be in basic, translational, clinical, or population sciences.

Max Amount and Period: $700,000 over 3 years

Eligibility: Applicants must be female investigators at the Associate Professor level with a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Applicants must also have received their first NIH R01 (or equivalent) award within the past 10 years (possible exceptions to the window may be granted for parental leave or other family leave). Applicants belonging to racial or ethnic groups shown to be underrepresented in the cancer-related sciences workforce* are especially encouraged to apply. These groups include Blacks or African Americans, Hispanics or Latinos, American Indians or Alaska Natives, Native Hawaiians and other Pacific Islanders. Applicants must have started their first independent faculty position within the past 6 years and be able to devote at least 75% of their total effort to research in breast or gynecologic cancer. There are no citizenship requirements.

Due Date: Letter of Intent Due: January 23, 2025 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The purpose of this administrative supplement is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. The supplemental request is required to be within the scope of the parent award and should expand the original aims to include a cancer disparity component and possible inclusion of international comparator cohorts. This announcement is for supplements to existing projects. To be eligible, the parent award must be active and the research proposed in the supplement must be accomplished within the competitive segment.

Max Amount and Period: $150,000 for 1 year

Eligibility: Applicants must hold an active grant or cooperative agreement, and the research proposed in the supplement must be accomplished within the competitive segment of the active award. Individuals are encouraged to work with their organizations to develop applications for support. For supplements to parent awards that include multiple PDs/PIs, the supplement may be requested by any or all of the PDs/PIs (in accordance with the existing leadership plan) and submitted by the awardee institution of the parent award.

Due Date: January 23, 2025 at 5pm CST

Additional Details

RFP Snapshot: This RFP is intended to support a clinical trial involving combination teclistamab and daratumumab for the treatment of AL amyloidosis. Mechanisms to foster collaborations within and among the Team will be employed—an approach that promotes the sharing of information and a goal-oriented focus on measurable milestones of progress. SU2C believes that this unique Team will advance scientific research in the interests of improved long-term outcomes for patients.

Max Amount and Period: $2M over 3 years

Eligibility: To maximize creativity, innovation, and collaboration, the Research Team must include members with appropriate expertise, with senior and early-career investigators, some of whom have not worked together in the past. The Team will consist of a Team Leader, a Team Co-Leader, at least one Team Principal, a Project Manager, and a Patient Advocate. Additionally, at least one of the leaders must have experience with clinical trials. There will be no more than two additional Team Principals, with a minimum of two participating institutions. Racial and ethnic diversity among Research Team personnel is strongly encouraged.

Due Date: January 28, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This RFP focuses on proposals to improve therapy management of metastatic breast cancer patients receiving tucatinib in combination with trastuzumab and capecitabine in clinical practice using innovative and community-accessible approaches that may impact patients adherence to treatment, quality of life, or symptom management, and/or facilitate follow-up in daily clinical practice.

Max Amount and Period: $250,000 over 18 months

Eligibility: Applicant must have a medical or postdoctoral degree (MD, PhD, or equivalent).

Due Date: January 30, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The intention of this grant is to help develop the next generation of research leaders who will blaze a path toward finding a cure for myelodysplastic syndromes (MDS). The Foundation is targeting support for promising candidates committed to the study of the biology, pathogenesis, and treatment of MDS as they make their transition to independent investigators.

Max Amount and Period: $450,000 over 3 years

Eligibility: The candidate should be an early career (typically within eight years of completing their last graduate degree) physician or scientist (MD, PhD, or MD-PhD), currently in a non-tenure track (or equivalent) position with a university, hospital, etc. Candidates should generally NOT hold the title of Assistant Professor and may not hold the title of Associate Professor or Professor. Individuals who are presently, or have in the past, been the principal investigator on any government or privately funded research grant (with the exception of an NIH training grant or similar) are not eligible for an EYIA grant. The Foundation encourages submissions from groups underrepresented in science.

Due Date: January 31, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The intention of this grant is to fund the discovery of new knowledge that will lead to the development of better MDS therapies and ultimately, disease cures. EvansMDS is conducting this competitive grant program to identify and fund research into the etiology, pathogenesis, and treatment of MDS that is collaborative, transformative, and of high impact. Priority will be given to projects that directly examine key features of MDS rather than general concepts in leukemia, hematopoiesis, aging or immunology.

Max Amount and Period: $750,000 over 3 years

Eligibility: Applicants must be established independent investigators in a tenure-track or tenured position at the Assistant Professor level (or equivalent), or higher, at a recognized 501(c)(3) university or non-profit institution in the United States. The Foundation values diversity and inclusiveness in its Discovery Research Grant Program and encourages submissions from groups underrepresented in science.

Due Date: Letter of Intent Due: January 31, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This RFA is to support pre-clinical, translational, and clinical research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas. The goal of the SFA grant program is to encourage research that results in improved therapeutic options for sarcoma patients. The SFA encourages applications in ALL areas of sarcoma research.

Max Amount and Period: $75,000 for 1 year

Eligibility: Applicants must be an MD, DO, PhD, or international equivalent, inside OR outside the US.

Due Date: February 3, 2025 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This RFA is to support pre-clinical, translational, and clinical research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas. The goal of the SFA grant program is to encourage research that results in improved therapeutic options for sarcoma patients. The SFA encourages applications in ALL areas of sarcoma research.

Max Amount and Period: $150,000 for 1 year

Eligibility: Applicants must be an MD, DO, PhD, or international equivalent. Applicants must be within the first ten years of faculty appointment.

Due Date: February 3, 2025 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This RFA is to support interventional clinical trials or clinical validation studies aimed at Improving the Early Detection of Lung Cancer through biomarkers and imaging.

Max Amount and Period: $1M over 3 years

Eligibility: Applicants must hold a doctoral degree and faculty appointment and may be at any level of research experience. Applicants must be independent, self-directed researchers for whom their institution provides space and other resources customary for independent investigators. The application must convey the commitment of the institution to both the applicant and the proposed research activities. An applicant with an existing Rising Tide award or a LUNGevity award that would be concurrent with Rising Tide/LUNGevity Award is precluded from applying. International teams are highly recommended and the award program does not have any geographical restrictions.

Due Date: Letter of Intent Due: February 12, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.